Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation

다국어 초록 (Multilingual Abstract)

Cancer remains a leading cause of death, despite multimodal treatment approaches. Even in patients with a healthy immune response, cancer cells can escape the immune system during tumorigenesis. Cancer cells incapacitate the normal cell-mediated immune system by expressing immune modulation ligands such as programmed death (PD) ligand 1, the B7 molecule, or secreting activators of immune modulators. Chimeric antigen receptor (CAR) T cells were originally designed to target cancer cells. Engineered approaches allow CAR T cells, which possess a simplified yet specific receptor, to be easily activated in limited situations. CAR T cell treatment is a derivative of the antigen-antibody reaction and can be applied to various diseases. In this review, the current successes of CAR T cells in cancer treatment and the therapeutic potential of CAR T cells are discussed.

참고문헌 (Reference)

1 Wei J, "miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma" 73 : 3913-3926, 2013

2 Binnewies M, "Understanding the tumor immune microenvironment(TIME)for effective therapy" 24 : 541-550, 2018

3 Rosso JD, "Understanding the epidermal barrier in healthy and compromised skin : clinically relevant information for the dermatology practitioner : proceedings of an expert panel roundtable meeting" 9 (9): S2-S8, 2016

4 Kochenderfer JN, "Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors" 10 : 267-276, 2013

5 Bonifant CL, "Toxicity and management in CAR T-cell therapy" 3 : 16011-, 2016

6 Brudno JN, "Toxicities of chimeric antigen receptor T cells : recognition and management" 127 : 3321-3330, 2016

7 Maude SL, "Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia" 378 : 439-448, 2018

8 Chames P, "Therapeutic antibodies : successes, limitations and hopes for the future" 157 : 220-233, 2009

9 Seliger B, "The complex role of B7 molecules in tumor immunology" 14 : 550-559, 2008

10 Aghajanian H, "Targeting cardiac fibrosis with engineered T cells" 573 : 430-433, 2019

11 Maus MV, "T cells expressing chimeric antigen receptors can cause anaphylaxis in humans" 1 : 26-31, 2013

12 Smith-Garvin JE, "T cell activation" 27 : 591-619, 2009

13 Sadelain M, "Safe harbours for the integration of new DNA in the human genome" 12 : 51-58, 2011

14 Chou FC, "Role of galectins in tumors and in clinical immunotherapy" 19 : E430-, 2018

15 Salles G, "Rituximab in B-cell hematologic malignancies : a review of 20years of clinical experience" 34 : 2232-2273, 2017

16 Nowrouzi A, "Retroviral vectors : post entry events and genomic alterations" 3 : 429-455, 2011

17 Hindmarsh P, "Retroviral DNA integration" 63 : 836-843, 1999

18 Ellebrecht CT, "Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease" 353 : 179-184, 2016

19 Greenman C, "Patterns of somatic mutation in human cancer genomes" 446 : 153-158, 2007

20 Plosker GL, "Omalizumab : a review of its use in the treatment of allergic asthma" 22 : 189-204, 2008

21 Anderson KG, "Obstacles posed by the tumor microenvironment to T cell activity : a case for synergistic therapies" 31 : 311-325, 2017

22 Luedde T, "NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma" 8 : 108-118, 2011

23 Singh S, "Monoclonal antibodies : a review" 13 : 85-99, 2018

24 Rosenblum MD, "Mechanisms of human autoimmunity" 125 : 2228-2233, 2015

25 Combs SE, "Loss of antigenicity with tissue age in breast cancer" 96 : 264-269, 2016

26 Normanno N, "Implications for KRAS status and EGFR-targeted therapies in metastatic CRC" 6 : 519-527, 2009

27 Beatty GL, "Immune escape mechanisms as a guide for cancer immunotherapy" 21 : 687-692, 2015

28 Barratt SL, "Idiopathic pulmonary fibrosis(IPF) : an overview" 7 : E201-, 2018

29 Lederer DJ, "Idiopathic pulmonary fibrosis" 378 : 1811-1823, 2018

30 Balogh J, "Hepatocellular carcinoma : a review" 3 : 41-53, 2016

31 Gill S, "Going viral : chimeric antigen receptor T-cell therapy for hematological malignancies" 263 : 68-89, 2015

32 Caruana I, "From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies" 41 : 661-666, 2014

33 Fan MH, "Fibroblast activation protein(FAP)accelerates collagen degradation and clearance from lungs in mice" 291 : 8070-8089, 2016

34 Zhang C, "Engineering CAR-T cells" 5 : 22-, 2017

35 Ledford H, "Engineered cell therapy for cancer gets thumbs up from FDA advisers" 547 : 270-, 2017

36 Gust J, "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells" 7 : 1404-1419, 2017

37 Andersen MH, "Cytotoxic T cells" 126 : 32-41, 2006

38 Dennis KL, "Current status of interleukin-10 and regulatory T-cells in cancer" 25 : 637-645, 2013

39 Lawn SD, "Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection" 14 : 753-777, 2001

40 Salmikangas P, "Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy - moving target for industry?" 35 : 152-, 2018

41 Brudno JN, "Chimeric antigen receptor T-cell therapies for lymphoma" 15 : 31-46, 2018

42 Nagarsheth N, "Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy" 17 : 559-572, 2017

43 Blick SK, "Cetuximab : a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer" 67 : 2585-2607, 2007

44 Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer" 348 : 124-128, 2015

45 Mollanoori H, "CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment" 79 : 876-882, 2018

46 Maude SL, "CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia" 125 : 4017-4023, 2015

47 Charrot S, "CAR-T cells : future perspectives" 3 : e188-, 2019

48 Hay AE, "CAR T-cells : costs, comparisons, and commentary" 22 : 613-615, 2019

49 Chavez JC, "CAR T-cell therapy for B-cell lymphomas : clinical trial results of available products" 10 : 2040620719841581-, 2019

50 Miliotou AN, "CAR T-cell therapy : a new era in cancer immunotherapy" 19 : 5-18, 2018

51 Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma" 377 : 2531-2544, 2017

52 "Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma" 60 : e122-e123, 2018

53 Thurber GM, "Antibody tumor penetration : transport opposed by systemic and antigen-mediated clearance" 60 : 1421-1434, 2008

54 Parkin J, "An overview of the immune system" 357 : 1777-1789, 2001

55 Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells" 25 : 625-638, 2019